Dr Komrokji on the Potential Implications of the COMMANDS trial in MDS
July 20th 2023Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.
Read More
Higher-Risk MDS: First- and Second-Line Therapies and Case 3 Presentation/Discussion
March 2nd 2023The panel turns their focus to higher-risk MDS, starting with a discussion of first- and second-line treatment options, followed by a third and final case presentation and discussion led by Dr Platzbecker.
Read More
First-Line Treatment Options for Lower-Risk MDS
January 26th 2023Thomas Cluzeau, MD, PhD provides an overview of first-line treatment options for symptomatic anemia in patients with lower-risk MDS, followed by a discussion of panelists’ treatment patterns and dosing strategies across the globe.
Read More
Dr. Komrokji Discusses the FDA Approval of Gilteritinib for FLT3+ AML
November 29th 2018Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the FDA approval of gilteritinib (Xospata) for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.
Read More